BioSpace News Archive

Pear Therapeutics, Inc., today announced publication of a new economic analysis describing the cost-effectiveness of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, announced today that it will be presenting at the 13th annual LD Micro Main Event investor conference.

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer, has been invited to make a presentation, entitled “Belapectin, a Galectin-3 Inhibitor in Phase 2b/3 for the Treatment of NASH Cirrhosis,” at the 4th Annual Digital NASH Summit.

Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Government of Canada officials will also hold a media technical briefing on data and modelling informing public health action on COVID-19. Date December 11, 2020 Time 10:00 AM (EST) Location S

Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced an agreement granting Elanco Animal Health Incorporated exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus (CPV).

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors.

ESCAPE Bio Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, announced that Edward Owens and Scott Morrison have been appointed to the Board of Directors.

Augmented adoption of face masks as a tool of precaution to safeguard oneself from different diseases, such Ebola, swine flu, avian bird flu, influenza, Covid-19, and anthrax has played an important role in the development of the global reusable face mask market.

Virtual clinical trials have emerged as a resilient addition to the portfolio of services offered by medical and healthcare research organizations.